TheScreener - Medartis AG (MED) MEDARTIS HOLDING sees a downgrade to Neutral on account of less fundamental stars

Report

TheScreener

EUR 13.72 For Business Accounts Only

MEDARTIS HOLDING sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MEDARTIS HOLDING (CH), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date March 22, 2022, the closing price was CHF 120.40 and its target price was estimated at CHF 103.39.

23/03/2022 1 EN

Underlying

Medartis AG

Medartis Holding AG is a Switzerland-based holding company of the Medartis Group, which is engaged in manufacturing medical devices and implants. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. It has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

See profile

CH0386200239 Six Swiss Exchange Switzerland

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Bryan Garnier

Medartis: Solid finish to 2024 with numerous strategic plans for 2025

Medartis reported FY2024 core sales growth of 11.7% (CER), placing it at the lower end of its updated guidance range of 12–15% post-H1, with total sales reaching CHF224.8mm (CHF219.6m core). Profitability outperformed expectations, delivering a 19.0% core EBITDA margin—up 1.9PP YoY versus guidance

March 18, 2025 March 18, 2025 1 EN

Bryan Garnier

Medartis: revising expectations ahead of FY'24 earnings, PT adjusted to CHF95

Medartis faced a volatile market in 2024, marked by a CEO transition and weaker-than-expected H1 performance in key geographies, prompting a downward revision of FY sales guidance to 12–15% CER (from 15–17%). Nonetheless, Medartis maintained its EBITDA margin guidance at ~15% CER, supported by cost

February 10, 2025 February 10, 2025 1 EN

Bryan Garnier

Medartis: US and EMEA sales ramp up but FY guidance downgraded

In H1 2024, the company reported underlying sales growth of 13.1% (CER), with total growth including third-party manufacturing at 10.8% CER, resulting in net sales of CHF 111.5m (CHF 103.3m). The US market led with a YoY growth of 20.6%, followed by EMEA at 17.8%, while growth in APAC and LATAM was

August 20, 2024 August 20, 2024 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS HOLDING sees a downgrade to Neutral on account of less fundamental stars

Empowering Investors

Medartis: Solid finish to 2024 with numerous strategic plans for 2025

Medartis: revising expectations ahead of FY'24 earnings, PT adjusted to CHF95

Medartis: US and EMEA sales ramp up but FY guidance downgraded

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe